MAC Clinical Research is proud to support Initiator Pharma as the full-service CRO partner for their upcoming Phase 2a clinical trial, as they take an important step forward in developing a potential new treatment for vulvodynia.
Initiator Pharma is a biotech company based in Denmark, working to develop new treatments for serious neurological conditions that currently have limited or no effective options.
They have just received UK regulatory and ethics approval to begin a Phase 2a clinical trial of IP2015, a candidate drug aimed at addressing this often-overlooked chronic pain condition.
Vulvodynia affects millions of women worldwide and is still without a specific, approved treatment. That’s why we are especially pleased to be involved in this study, not only as the full-service CRO partner, but also as a funding partner through a convertible credit agreement to support the trial’s delivery.
The study will run at MAC’s UK research sites and is designed to explore the safety, tolerability and early signs of efficacy of IP2015 using a crossover design.
With this approval in place – we are now moving ahead with patient enrolment in partnership with Initiator Pharma and are on track to dose the first participants before the end of the year, with results anticipated in 2026.
